Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | GRB2 | P62993 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8267301 | 0.94 | PTPN1 (0.61) | PTPN1CTSLCTSKMDM2GRB2 | |
| SCHEMBL2735616 | 0.91 | PTPN1 (0.58) | PTPN1CAPN1 | |
| SCHEMBL29398078 | 0.91 | PTPN1 (0.58) | PTPN1CAPN1 | |
| SCHEMBL29445591 | 0.91 | MDM2 (0.59) | PTPN1MDM2 | |
| SCHEMBL2304915 | 0.91 | MDM2 (0.59) | PTPN1MDM2 | |
| SCHEMBL2304920 | 0.91 | MDM2 (0.59) | PTPN1MDM2 | |
| SCHEMBL3724885 | 0.91 | MDM2 (0.59) | PTPN1MDM2 | |
| SCHEMBL29397862 | 0.91 | MDM2 (0.59) | PTPN1MDM2 | |
| SCHEMBL30686153 | 0.91 | MDM2 (0.59) | PTPN1MDM2 | |
| SCHEMBL10106060 | 0.90 | PTPN1 (0.58) | PTPN1MDM2CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-08-04 | — | — | US | disclosed |
| US-20120329705-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS, INC. | 2012-12-27 | — | — | US | disclosed |
| US-8198270-B2 | Compounds for proteasome enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20090131421-A1 | Compounds for proteasome enzyme inhibition | ONYX THERAPEUTICS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-7417042-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2006017842-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | PTPN1 643/4885CTSL 372/4885CTSK 181/4885 |
| US-20120329705-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | PTPN1 643/4885CTSL 372/4885CTSK 181/4885 |
| US-20090131421-A1 | Compounds for proteasome enzyme inhibition | PSMB1, PSMB9, PSMB3 | PTPN1 643/4885CTSL 372/4885CTSK 181/4885 |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | PTPN1 906/4885CTSL 173/4885CTSK 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.